147 related articles for article (PubMed ID: 35091711)
1. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
[TBL] [Abstract][Full Text] [Related]
2. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
Yang X; Allen JC; Aslim EJ; Tay KJ; Yuen SPJ; Kanesvaran R; Chua MLK; Chong TW; Ho SSH; Lee LS
Int J Urol; 2022 Nov; 29(11):1322-1330. PubMed ID: 36000794
[TBL] [Abstract][Full Text] [Related]
4. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
7. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
[TBL] [Abstract][Full Text] [Related]
8. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
9. Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.
Ilario EN; Bastos DA; Guglielmetti GB; Murta CB; Cardili L; Cordeiro MD; Junior JP; Coelho RF; Nahas WC
Clin Genitourin Cancer; 2023 Feb; 21(1):43-54. PubMed ID: 36428171
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
[TBL] [Abstract][Full Text] [Related]
11. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
12. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
13. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
[TBL] [Abstract][Full Text] [Related]
14. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA
J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439
[TBL] [Abstract][Full Text] [Related]
15. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Dirix P; Strijbos M; den Mooter TV; Liefhooghe N; Bruwaene SV; Uvin P; Ghysel C; Ost D; Schatteman P; Bral S; Engels B; den Begin RV; Otte FX; Roumeguere T; Palumbo S; Neybuch Y; Fonteyne V; Ost P; Dirix L
Future Oncol; 2020 Jun; 16(16):1083-1189. PubMed ID: 32356465
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
[TBL] [Abstract][Full Text] [Related]
17. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
[TBL] [Abstract][Full Text] [Related]
19. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
20. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Rabbani F; Goldenberg SL; Klotz LH
J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
